Norgine has welcomed the
PBS listing of Xifaxan (rifaximin)
550 for the treatment of hepatic
encephalopathy, which is a
deterioration of brain function that
happens when the liver is no longer
able to remove toxic substances
from the blood.
Twice daily Xifaxan treatment
plus lactulose treatment has been
shown to reduce the risk of a
breakthrough HE episode by 58%.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.